GE HealthCare Launches Flyrcado Injection to Treat CAD

March 27, 2025—GE HealthCare announced the United States launch of Flyrcado (flurpiridaz F 18) injection, which received FDA approval in 2024 for patients with known or suspected coronary artery disease.

CMS Initiates NCA on Renal Denervation for Uncontrolled Hypertension

January 13, 2025—Medtronic and Recor Medical, Inc. separately announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA; CAG-00470N) on renal denervation (RDN) for uncontrolled hypertension.

CMS Seeks Comments on Proposed Decision Memo for TTVR Coverage

January 7, 2025—The Centers for Medicare & Medicaid Services (CMS) is seeking comments on its proposed decision memo for a national coverage determination (NCD) for transcatheter tricuspid valve replacement (TTVR).

Cleerly’s AI-QCT Advanced Plaque Analysis Receives CPT Category I Code

November 8, 2024—Cleerly recently announced that the American Medical Association (AMA) has approved a Current Procedural Terminology (CPT) Category I code for its artificial intelligence–enabled quantitative coronary tomography (AI-QCT) advanced plaque analysis.

HeartFlow’s CCTA Outpatient Reimbursement Increased by CMS

November 8, 2024—HeartFlow, Inc. recently announced that the Centers for Medicare & Medicaid Services (CMS) released a final rule elevating the ambulatory payment classification (APC) of coronary computed tomography angiography (CCTA).

AMA Issues Category I CPT Code for AI-Enabled Plaque Quantification Technology

October 18, 2024—HeartFlow, Inc., a developer of noninvasive artificial intelligence (AI) heart care solutions, announced that the American Medical Association (AMA) has issued a new Category I Current Procedural Terminology (CPT) code for AI-enabled plaque quantification technology, including the company’s HeartFlow Plaque Analysis, effective January 2026.

CMS Updates Coverage for AI Coronary Plaque Analysis

October 15, 2024—The Society of Cardiovascular Computed Tomography (SCCT) announced that four of the seven Medicare Administrative Contractors (MACs) released final local coverage determinations (LCD) for artificial intelligence (AI) coronary plaque analysis (AI CPA).

UK NICE Draft Guidance Reports No Evidence to Justify Price Variation of TAVI Devices in NHS

August 22, 2024—The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently announced a Draft Guidance on heart valves used in transcatheter aortic valve implantation (TAVI) by the National Health Services (NHS).

CMS Approves NTAP for Renal Denervation

August 12, 2024—The Centers for Medicare & Medicaid Services (CMS) recently issued the Final Rule for FY2025 Hospital Inpatient Prospective Payment Systems, which includes a New Technology Add-On Payment (NTAP) for renal denervation (RDN) procedures using new devices.

CMS Establishes New Category I CPT Add-On Code for Coronary IVL

November 3, 2023—Shockwave Medical, Inc., announced today that as part of the Calendar Year 2024 Physician Fee Schedule (PFS) final rule, the United States Centers for Medicare & Medicaid Services (CMS) has established a Category I Current Procedural Terminology (CPT) add-on code for procedures involving coronary intravascular lithotripsy (IVL).

Procyrion’s Aortix pMCS Will Be Covered Under New CMS Codes in DRAIN-HF Pivotal Trial

September 7, 2023—Procyrion, Inc. announced new inpatient hospital ICD-10-PCS procedure codes from the Centers for Medicare & Medicaid Services (CMS) that are applicable to the company’s Aortix percutaneous mechanical circulatory support (pMCS) technology.

Shockwave Announces New CMS Codes and Increased Payments for Coronary Intravascular Lithotripsy

August 2, 2023—Shockwave Medical, Inc., a developer of intravascular lithotripsy (IVL) technology to treat severely calcified cardiovascular disease, announced that the Centers for Medicare & Medicaid Services (CMS) created a new Medicare Severity Diagnosis Related Group (MS-DRG) codes and payments for coronary IVL in the hospital inpatient setting.

Neovasc Reducer Obtains Outpatient Reimbursement From CMS

November 8, 2022—Neovasc, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) have assigned the Neovasc Reducer implant procedure a new outpatient reimbursement code payment status indicator, enabling hospitals in the United States to be reimbursed for the device and implant procedure.

Diagnosis Code Designated for Refractory Angina Pectoris

October 20, 2022—The Society for Cardiovascular Angiography & Interventions (SCAI) recently announced that new ICD-10-CM codes have been added to properly reflect and document the condition of refractory angina pectoris.

BioCardia’s CardiAMP Cell Therapy Procedure Receives CMS Code for Use in Clinical Trials

March 22, 2022—BioCardia, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has designated a new reimbursement code for the CardiAMP cell therapy procedure to transplant autologous bone marrow cells to treat heart failure.

SCAI’s Government Relations Committee Outlines Efforts to Fight Cuts in Medicare Proposed Fee Schedule

August 25, 2021—The Government Relations Committee of the Society for Cardiovascular Angiography & Interventions (SCAI) has posted a brief overview of the cuts related to interventional cardiology from the Medicare Proposed Fee Schedule issued by the Centers for Medicare & Medicaid Services (CMS).

AngioDynamics’ AngioVac Treatment Included Under New AMA Category III CPT Code for Transcatheter Removal/Debulking of Intracardiac Masses

August 24, 2021—AngioDynamics, Inc. advised that new Category III CPT code approved by the American Medical Association (AMA) CPT Panel gives physicians an updated billing code for use of the company’s AngioVac system for removal of undesirable intravascular material in the right heart.